1. When changes in urine flow rate were induced by vasopressin administration in eight subjects, urate excretion decreased by a mean of 14% and was positively correlated with urine flow rate (r = 0.88, PcO-01). The effect of vasopressin on urate excretion was not influenced by prior changes in extracellular fluid volume.
Introduction
. Urate excretion in man has been shown to increase both with increased urine flow rate (Diamond, Lazarus, Kaplan & Halberstam, 1972 ; Brockner-Mortenson, 1937 ) and after extracellular fluid volume expansion (Stele, 1969; Cannon, Svahn & &Martini, 1970) . In a previous report, the uricosuria associated with increased urine flow rate in the apparent absence of expansion of extracellular fluid volume was attributed to diminished urate reabsorption in the collecting duct (Diamond et al., 1972) . In that study, changes in urine flow rate were induced by alteration in oral water load. Thus concomitant minor changes in extracellular fluid volume could not be entirely excluded.
In the present study, changes in urine flow rate were induced by administration of vasopressin to further define the effect of urine flow rate on urate excretion in man. Vasopressin was administered under various conditions of water load so as to distinguish between the effect of volume load and urine flow rate on urate excretion.
Methods

Subjects and clearance stiidies
All studies were carried out after obtaining signed informed consent based upon a protocol approved Thirty-five clearance studies were carried out in nine healthy male volunteer subjects, ranging in age from 27 to 67 years. All subjects had a blood urea nitrogen of less than 4.1 mmol/l. All subjects were admitted to the Clinical Research Center and maintained on a normal protein, constant purine, constant food-energy diet. All medications affecting serum urate concentrations were discontinued at least 1 week before the studies, and 3 days were allowed for dietary adjustment. All studies were conducted in the morning after an overnight fast. Urine was collected by voiding. Prolonged collection periods were utilized after vasopressin administration to ensure that all urine collections were greater than 50 ml.
Glomerular filtration rate was estimated on the basis of endogenous creatinine clearance. Creatinine was determined by the Auto-Analyzer method (Technicon Corp., Tarrytown, N.Y., U.S.A.). Creatinine excretion has been determined in all urine collections in studies involving pyrazinamide administration in this laboratory over the past 5 years. Creatinine excretion and clearance have not been altered by pyrazinamide administration. Urate was determined by an enzymatic spectrophotometric technique (Crowley & Alton, 1968) . Sodium was measured by an automated technique (Mabry, Gevedon, Roeckel & Gochman, 1966) .
Studies were performed according to the following protocols.
Lysinr vasopressin without volume expansion
Sufficient distilled water was administered orally to establish a steady state of urine flow at a rate of approximately 5 ml/min. Thereafter, water was administered only to replace urinary losses. Two or three control clearance periods of approximately 20 min were obtained with a venous blood sample obtained in the middle of each period. At the conclusion of these control urine collections, 10 units of lysine vasopressin were administered intramuscularly. Two additional clearance intervals of 60-90 min were then obtained. Values for control and post-vasopressin excretion were calculated as the mean of all the control and all the vasopressin clearance intervals respectively.
Administration of lysine vasopression during constant mannitol infusion
In three subjects, mannitol(25 g) was administered as a primary injection intravenously over 5 min, followed by a constant intravenous infusion of mannitol (200 g/l) at a rate of 5 ml/min. Two control clearance intervals of 15-20 min each were obtained after the start of the mannitol infusion. Although mannitol infusion would be expected to cause endogenous vasopressin release, 10 units of lysine vasopressin were administered intramuscularly. Three additional clearance intervals of 15-20 min were obtained. Values for mannitol and postvasopressin periods were calculated as the mean of all the control and all the post-vasopressin intervals respectively.
Pyrarinamide studies
In studies of the effect of pyrazinamide on urate excretion, pyrazinamide (3 g) was administered after two control clearance intervals. Water was administered only to replace urinary loss. Lysine vasopressin (10 units) was administered 90 min after pyrazinamide at the start of a clearance interval. The effect of pyrazinamide on control urate excretion was assessed by similar studies in which administration of vasopressin was omitted. For each clearance study, pyrazinamide-suppressible urate excretion was calculated as the mean urate excretion for the two control periods minus urate excretion in the period after administration of pyrazinamide. The latter value is referred to as post-pyrazinamide urate excretion.
Lysine vasopressin followed by volume expansion
In six subjects, two initial control clearance intervals were followed by the administration of lysine vasopressin. The subjects then drank 500-1000 ml of water/h throughout the remainder of the study. After 2 h, two 45 min clearance periods were obtained with venous blood samples in the middle of each clearance interval. Subjects were weighed immediately after vasopressin administration and at the conclusion of the study.
Results have been expressed as mean values f SEM.
Statistical comparison was made with either paired or unpaired t-tests as appropriate. Values less than P = 0.05 were considered significant.
Results
The effects of administration of lysine vasopressin without water loading are summarized in Table 1 and Fig. 1 . Vasopressin administration reduced the mean urine flow rate from 4.5k1.4 ml/min to 1.9kO.7 ml/min and increased the mean urine sodium concentration from 2.2 f0.7 mmol/l to 4.2 f 1.3 mmol/l. The mean urate excretion decreased by 14%, from 2.98 f0.22 .umol/min during control collections to 2.57 k0.23 pmol/min after vasopressin. Decreased urate excretion was observed in all six subjects ( Fig. 1) . There was no change in serum urate concentration. Urate clearance and the urate clearance/glomerular filtration rate ratio also decreased. Urate excretion and urine flow rate were positively correlated (r = 0.88, P< 0.01).
Glomerular filtration rate did not change after administration of vasopressin. A small increment in sodium excretion after administration of vasopressin occurred in the four patients studied, but the increase was not statistically significant. In order to demonstrate that vasopressin-induced urate retention was not due to inadvertent volume contraction, in two subjects (Table 1 b) volume expansion was induced by administration of a net excess of 3.5 1 of water (excess of intake over urinary output) before the administration of vasopressin. Volume expansion was confirmed by a mean weight gain of 3.5 kg and an increase in sodium excretion. Thereafter, water was administered only in quantities sufficient to replace urinary loss. Urine collections were then carried out as for the subjects who were not volumeexpanded. Administration of vasopressin after volume expansion resulted in a decrease in urine flow rate in both subjects and a concomitant decrease in urate excretion (Table lb) .
To determine whether vasopressin had a direct effect on urate excretion or whether the effect of vasopressin was secondary to changes in urine flow rate, vasopressin was administered during a constant mannitol infusion ( Table 2) . During mannitol infusion, administration of vasopressin did not decrease urine flow rate. Urate excretion was not changed by administration of vasopressin during mannitol infusion.
The effect of pyrazinamide on urate excretion was assessed in five subjects under control conditions and after vasopressin (Table 3) . Urate retention after vasopressin was entirely attributed to a decrease in pyrazinamide-suppressible urate excretion, which decreased from a mean value of 2 5 f0.24 pmol/min to 2.1 f0-27 pmol/min, consistent with either decreased urate secretion or enhanced post-secretory reabsorption of urate. Post-pyrazinamide urate excretion was unchanged.
Volume expansion is known to be uricosuric in man (Steele, 1969; Cannon et a]., 1970). In six subjects, volume expansion was induced by oral water intake sufficient to produce a mean positive Table 4) . There was a mean increase of 3.5 kg in body weight and an increase in mean urine sodium excretion from 2.0 mmol/min to 4.8 mmoll min. Administration of vasopressin did not prevent the uricosuric response to volume expansion. Mean urate excretion increased from a control value of 2.94 pmol/min to 3.72 pmollmin after vasopressin and volume expansion. Serum urate did not change and urate clearance increased from 8.5 ml/min to 10.7 mllmin. Urine flow rate was decreased after vasopressin even in the presence of volume expansion (control 4.8 ml/min; vasopressin plus volume expansion 1.3 ml/min). In five of these six subjects, the volume-expansion study was repeated a second time except that pyrazinamide (3 g) was administered 90 min before administration of vasopressin ( Table 5 ). In these five subjects, volume expansion after vasopressin was associated with an increase in pyrazinamidesuppressible urate excretion from 253 pmollmin 
Discussion
The diminished urate excretion which followed vasopressin administration in the present study is consistent with the earlier observation of a significant association of urate excretion with urine flow rate in man (Diamond et al., 1972; Brockner-Mortenson, 1937) . Changes in filtered load of urate did not account for the diminished urate excretion after vasopressin. The small but consistent increase in glomerular filtration rate observed after administration of vasopressin would increase the filtered load of urate and might increase excretion.
Contraction of extracellular fluid volume is associated with urate retention (Steele & Oppenheimer, 1969 ) and extracellular fluid volume expansion results in enhanced urate excretion (Steele , 1970) . The alteration in urate excretion produced by changes in extracellular fluid volume can be distinguished from the urate retaining effect of vasopressin-mediated decrease in urine flow. In the present study, vasopressin-induced urate retention occurred even when vasopressin was administered after volume expansion. Thus urate retention after administration of vasopressin could not be attributed to volume contraction. When flow rate was held constant after administration of vasopressin, the expected uricosuric response to extracellular fluid volume expansion was observed. In the latter studies, there were probably two opposite effects on urate excretion: the uricosuric response to extracellular fluid volume expansion and the anti-uricosuric effect of vasopressin administration.
Vasopressin may inhibit solute reabsorption in the loop of Henle (Antoniou, Burke, Robinson & Clapp, 1973 ), but does not appear to alter solute transport in the proximal tubule. Alterations in extracellular fluid volume appear to modulate solute reabsorption in the proximal renal tubule (Diamond & Meisel, 1975) . Clearance studies and direct intratubular micro-injections in the rat have demonstrated that net urate reabsorption is influenced by the state of hydration, and that these alterations are mediated by changes in the rates of reabsorption in the proximal tubule (Weinman, Eknoyan & Suki, 1975) . Decrease in urine flow rate resulted in diminished urate excretion even when vasopressin was administered after volume expansion. Effects of flow rate on urate transport appear to be independent of alterations in solute transport in the proximal renal tubule.
The acute changes demonstrated in the present study are consistent with clinical and laboratory observations associated with chronicvolume changes. Uricosuria has been observed in volumeexpanded patients with inappropriate antidiuretic hormone syndrome, and in normal subjects in whom chronic volume expansion was induced by the administration of vasopressin and water loading (Mees, van Assendelft & Nieuwenhuis, 1971) . Vasopressinresistant diabetes insipidus results in chronic volume depletion and urate retention in spite of high urine flow rates (Gordon, Robertson & Seegmiller, 1971) . Oral administration of pyrazinamide in man is associated with a decrease in urate excretion permitting subdivision of excreted urate into pyrazinamide-suppressible and post-pyrazinamide fractions (Steele & Reiselbach, 1967; Gutman, Yu & Berger, 1969) . The decrease in the pyrazinamide-suppressible fraction of total urate excretion after vasopressin is similar to that observed when diminished urine flow rate was induced by decreased water intake (Diamond et a/., 1972) . Diminished pyrazinamide-suppressible urate excretion at low urine flow rate has been considered to represent enhanced post-secretory urate reabsorption (Diamond et al., 1972) . Alternatively, diminished pyrazinamide-suppressible urate excretion might reflect inhibition of urate secretion by lysine vasopressin. This appears unlikely since similar results have previously been obtained when urine flow rate was diminished by decreasing water intake without the use of vasopressin (Diamond et al., 1972) . Moreover, when volume expansion was induced after lysine vasopressin, both pyrazinamidesuppressible and post-pyrazinamide urate excretion increased. An increase in pyrazinamide-suppressible urate excretion would not be expected if urate secretion were inhibited by lysine vasopressin.
Microperfusion and free-flow studies of urate transport in the rat kidney have demonstrated bidirectional transport of urate with net secretion in the proximal tubule and net reabsorption distal to the proximal tubule (Greger, Lang & Deetjen, 1971; Lang, Greger & Deetjen, 1972) . Although most reabsorption distal to the proximal tubule probably occurred in the loop of Henle, these results are consistent with some urate reabsorption in the distal part of the nephron.
In the Cebus monkey, micropuncture and stopflow studies have localized urate reabsorption predominantly to the proximal tubule (Roch-Ramel & Weiner, 1973) . However, these studies were consistent with reabsorption of a small fraction of filtered urate in the distal part of the nephron, accounting for less than 13% of net urate reabsorption. Theenhanced uratereabsorption associated with administration of vasopressin is most likely localized to the distal nephron tubule or collecting duct. Alterations in urine flow rate and permeability resulting from administration of vasopressin are probably localized to the distal nephron tubule and collecting duct (Handler & Orloff, 1973) . Since vasopressin accelerates transport of uric acid by the toad bladder (Levine, Franki & Hays, 1974) , it may accelerate urate reabsorption in the collecting duct in man. This would also represent enhanced post-secretory urate reabsorption by vasopressin and would be associated with a decrease in pyrazinamide-suppressible urate excretion (Diamond et al., 1972; Diamond & Paolino, 1973) . Alternatively, vasopressin may have a direct effect on postproximal solute transport in the loop of Henle (Antoniou et a]., 1973) . Since reabsorption of other solutes in the loop of Henle decreases with increases in flow rate (Greger, Lang & Deetjen, 1974) , prior administration of mannitol might inhibit urate reabsorption at this site and therefore might block an anti-uricosuric effect of vasopressin in the loop of Henle. This hypothesis would not explain the uricosuric effect induced by altering water intake in the absence of volume expansion.
Urate retention after administration of vasopressin occurred only when there was an accompanying decrease in urine flow rate. Administration of mannitol in a dose sufficient to prevent vasopressininduced alterations in urine flow rate blocked the effect of vasopressin on urate excretion. Thus urate retention after vasopressin can be attributed to diminished distal tubular urine flow rather than to a direct effect of vasopressin.
The decrease in urate reabsorption induced by vasopressin-mediated decrease in urine flow rate represents only approximately 2% of net urate reabsorption in man. Thus the postulated reabsorptive site for urate in the distal part of the nephron probably accounts for only a minor portion of total urate reabsorption. However, the terminal location of this reabsorptive site in the nephron may permit a significant modulation of urate reabsorption. The mean change in excreted urate associated with changes in urine flow in the present study was 14%. The postulated reabsorptive site in the distal part of the nephron may be of physiological significance in reducing high urine urate concentrations during uricosuria at low rates of urine flow.
